nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCB11—Cyclosporine—psoriasis	0.0474	0.0838	CbGbCtD
Ponatinib—CYP2C8—Tazarotene—psoriasis	0.0428	0.0757	CbGbCtD
Ponatinib—CYP3A5—Beclomethasone—psoriasis	0.0414	0.0732	CbGbCtD
Ponatinib—ABCB11—Dexamethasone—psoriasis	0.0312	0.0552	CbGbCtD
Ponatinib—ABCG2—Mycophenolate mofetil—psoriasis	0.0297	0.0526	CbGbCtD
Ponatinib—ABCG2—Hydrocortisone—psoriasis	0.0238	0.0422	CbGbCtD
Ponatinib—ABCG2—Cyclosporine—psoriasis	0.0225	0.0399	CbGbCtD
Ponatinib—CYP2D6—Hydroxyurea—psoriasis	0.0192	0.034	CbGbCtD
Ponatinib—CYP2C8—Cholecalciferol—psoriasis	0.0183	0.0323	CbGbCtD
Ponatinib—CYP3A5—Mycophenolate mofetil—psoriasis	0.0165	0.0291	CbGbCtD
Ponatinib—CYP2C8—Mycophenolate mofetil—psoriasis	0.0158	0.028	CbGbCtD
Ponatinib—ABCG2—Dexamethasone—psoriasis	0.0148	0.0262	CbGbCtD
Ponatinib—CYP3A4—Calcitriol—psoriasis	0.0144	0.0254	CbGbCtD
Ponatinib—CYP3A5—Hydrocortisone—psoriasis	0.0132	0.0234	CbGbCtD
Ponatinib—CYP2C8—Hydrocortisone—psoriasis	0.0127	0.0225	CbGbCtD
Ponatinib—CYP3A5—Cyclosporine—psoriasis	0.0125	0.0221	CbGbCtD
Ponatinib—CYP2C8—Cyclosporine—psoriasis	0.012	0.0212	CbGbCtD
Ponatinib—ABCG2—Methotrexate—psoriasis	0.0119	0.0211	CbGbCtD
Ponatinib—CYP2D6—Cholecalciferol—psoriasis	0.0116	0.0206	CbGbCtD
Ponatinib—CYP3A4—Methoxsalen—psoriasis	0.0112	0.0198	CbGbCtD
Ponatinib—ABCB1—Mycophenolate mofetil—psoriasis	0.0107	0.019	CbGbCtD
Ponatinib—ABCB1—Betamethasone—psoriasis	0.00919	0.0163	CbGbCtD
Ponatinib—ABCB1—Prednisolone—psoriasis	0.00907	0.0161	CbGbCtD
Ponatinib—ABCB1—Hydrocortisone—psoriasis	0.0086	0.0152	CbGbCtD
Ponatinib—ABCB1—Prednisone—psoriasis	0.00857	0.0152	CbGbCtD
Ponatinib—CYP3A5—Dexamethasone—psoriasis	0.00822	0.0145	CbGbCtD
Ponatinib—ABCB1—Cyclosporine—psoriasis	0.00812	0.0144	CbGbCtD
Ponatinib—CYP2C8—Dexamethasone—psoriasis	0.0079	0.014	CbGbCtD
Ponatinib—CYP2D6—Cyclosporine—psoriasis	0.00765	0.0135	CbGbCtD
Ponatinib—CYP3A4—Cholecalciferol—psoriasis	0.0074	0.0131	CbGbCtD
Ponatinib—FGFR3—skin epidermis—psoriasis	0.00666	0.177	CbGeAlD
Ponatinib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00642	0.0114	CbGbCtD
Ponatinib—CYP3A4—Triamcinolone—psoriasis	0.00642	0.0114	CbGbCtD
Ponatinib—CYP3A4—Betamethasone—psoriasis	0.00551	0.00975	CbGbCtD
Ponatinib—CYP3A4—Prednisolone—psoriasis	0.00544	0.00962	CbGbCtD
Ponatinib—ABCB1—Dexamethasone—psoriasis	0.00535	0.00946	CbGbCtD
Ponatinib—FGFR4—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.00518	1	CbGdCrCtD
Ponatinib—CYP3A4—Hydrocortisone—psoriasis	0.00515	0.00912	CbGbCtD
Ponatinib—CYP3A4—Prednisone—psoriasis	0.00513	0.00908	CbGbCtD
Ponatinib—CYP2D6—Dexamethasone—psoriasis	0.00504	0.00892	CbGbCtD
Ponatinib—CYP3A4—Cyclosporine—psoriasis	0.00487	0.00861	CbGbCtD
Ponatinib—FGFR2—skin epidermis—psoriasis	0.00436	0.116	CbGeAlD
Ponatinib—ABCB1—Methotrexate—psoriasis	0.0043	0.0076	CbGbCtD
Ponatinib—CYP3A4—Dexamethasone—psoriasis	0.0032	0.00567	CbGbCtD
Ponatinib—TEK—endothelium—psoriasis	0.00303	0.0804	CbGeAlD
Ponatinib—KIT—skin epidermis—psoriasis	0.00303	0.0802	CbGeAlD
Ponatinib—SRC—endothelium—psoriasis	0.0027	0.0714	CbGeAlD
Ponatinib—KDR—endothelium—psoriasis	0.00248	0.0657	CbGeAlD
Ponatinib—KIT—endothelium—psoriasis	0.0022	0.0582	CbGeAlD
Ponatinib—FGFR3—skin of body—psoriasis	0.00206	0.0547	CbGeAlD
Ponatinib—BCR—tendon—psoriasis	0.00136	0.036	CbGeAlD
Ponatinib—FGFR2—skin of body—psoriasis	0.00135	0.0358	CbGeAlD
Ponatinib—FGFR1—tendon—psoriasis	0.00121	0.032	CbGeAlD
Ponatinib—SRC—skin of body—psoriasis	0.00115	0.0305	CbGeAlD
Ponatinib—RET—tendon—psoriasis	0.00108	0.0287	CbGeAlD
Ponatinib—TEK—tendon—psoriasis	0.000986	0.0261	CbGeAlD
Ponatinib—KIT—skin of body—psoriasis	0.000938	0.0249	CbGeAlD
Ponatinib—PDGFRA—tendon—psoriasis	0.000894	0.0237	CbGeAlD
Ponatinib—ABL1—skin of body—psoriasis	0.000817	0.0216	CbGeAlD
Ponatinib—KDR—tendon—psoriasis	0.000806	0.0214	CbGeAlD
Ponatinib—ABL1—tendon—psoriasis	0.000622	0.0165	CbGeAlD
Ponatinib—Dyspnoea—Cyclosporine—psoriasis	9.13e-05	0.000396	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	9.1e-05	0.000395	CcSEcCtD
Ponatinib—Oedema—Hydrocortisone—psoriasis	9.1e-05	0.000395	CcSEcCtD
Ponatinib—Asthenia—Mycophenolic acid—psoriasis	9.08e-05	0.000394	CcSEcCtD
Ponatinib—Hypertension—Triamcinolone—psoriasis	9.06e-05	0.000393	CcSEcCtD
Ponatinib—Infection—Hydrocortisone—psoriasis	9.04e-05	0.000392	CcSEcCtD
Ponatinib—Insomnia—Mycophenolate mofetil—psoriasis	9.03e-05	0.000392	CcSEcCtD
Ponatinib—Dyspepsia—Cyclosporine—psoriasis	9.01e-05	0.000391	CcSEcCtD
Ponatinib—Hyperhidrosis—Prednisolone—psoriasis	9.01e-05	0.000391	CcSEcCtD
Ponatinib—Nausea—Hydroxyurea—psoriasis	8.97e-05	0.000389	CcSEcCtD
Ponatinib—Paraesthesia—Mycophenolate mofetil—psoriasis	8.97e-05	0.000389	CcSEcCtD
Ponatinib—Pruritus—Mycophenolic acid—psoriasis	8.95e-05	0.000388	CcSEcCtD
Ponatinib—Myalgia—Triamcinolone—psoriasis	8.94e-05	0.000388	CcSEcCtD
Ponatinib—Nervous system disorder—Hydrocortisone—psoriasis	8.92e-05	0.000387	CcSEcCtD
Ponatinib—Pneumonia—Methotrexate—psoriasis	8.92e-05	0.000387	CcSEcCtD
Ponatinib—Eye disorder—Prednisone—psoriasis	8.9e-05	0.000386	CcSEcCtD
Ponatinib—Dyspnoea—Mycophenolate mofetil—psoriasis	8.9e-05	0.000386	CcSEcCtD
Ponatinib—Decreased appetite—Cyclosporine—psoriasis	8.9e-05	0.000386	CcSEcCtD
Ponatinib—Infestation NOS—Methotrexate—psoriasis	8.87e-05	0.000385	CcSEcCtD
Ponatinib—Infestation—Methotrexate—psoriasis	8.87e-05	0.000385	CcSEcCtD
Ponatinib—Flushing—Prednisone—psoriasis	8.84e-05	0.000384	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Cyclosporine—psoriasis	8.84e-05	0.000383	CcSEcCtD
Ponatinib—Skin disorder—Hydrocortisone—psoriasis	8.84e-05	0.000383	CcSEcCtD
Ponatinib—Fatigue—Cyclosporine—psoriasis	8.83e-05	0.000383	CcSEcCtD
Ponatinib—Hyperhidrosis—Hydrocortisone—psoriasis	8.8e-05	0.000382	CcSEcCtD
Ponatinib—Dyspepsia—Mycophenolate mofetil—psoriasis	8.79e-05	0.000381	CcSEcCtD
Ponatinib—Pain—Cyclosporine—psoriasis	8.75e-05	0.00038	CcSEcCtD
Ponatinib—Constipation—Cyclosporine—psoriasis	8.75e-05	0.00038	CcSEcCtD
Ponatinib—Dry mouth—Triamcinolone—psoriasis	8.74e-05	0.000379	CcSEcCtD
Ponatinib—Decreased appetite—Mycophenolate mofetil—psoriasis	8.68e-05	0.000377	CcSEcCtD
Ponatinib—Diarrhoea—Mycophenolic acid—psoriasis	8.66e-05	0.000376	CcSEcCtD
Ponatinib—Stomatitis—Methotrexate—psoriasis	8.65e-05	0.000375	CcSEcCtD
Ponatinib—Angiopathy—Prednisone—psoriasis	8.64e-05	0.000375	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	8.62e-05	0.000374	CcSEcCtD
Ponatinib—Oedema—Triamcinolone—psoriasis	8.57e-05	0.000372	CcSEcCtD
Ponatinib—Constipation—Mycophenolate mofetil—psoriasis	8.54e-05	0.00037	CcSEcCtD
Ponatinib—Pain—Mycophenolate mofetil—psoriasis	8.54e-05	0.00037	CcSEcCtD
Ponatinib—Arrhythmia—Prednisone—psoriasis	8.51e-05	0.000369	CcSEcCtD
Ponatinib—Infection—Triamcinolone—psoriasis	8.51e-05	0.000369	CcSEcCtD
Ponatinib—Insomnia—Prednisolone—psoriasis	8.43e-05	0.000366	CcSEcCtD
Ponatinib—Alopecia—Prednisone—psoriasis	8.42e-05	0.000365	CcSEcCtD
Ponatinib—Hepatobiliary disease—Methotrexate—psoriasis	8.39e-05	0.000364	CcSEcCtD
Ponatinib—Gastrointestinal pain—Cyclosporine—psoriasis	8.37e-05	0.000363	CcSEcCtD
Ponatinib—Dizziness—Mycophenolic acid—psoriasis	8.37e-05	0.000363	CcSEcCtD
Ponatinib—Epistaxis—Methotrexate—psoriasis	8.37e-05	0.000363	CcSEcCtD
Ponatinib—Paraesthesia—Prednisolone—psoriasis	8.36e-05	0.000363	CcSEcCtD
Ponatinib—Mental disorder—Prednisone—psoriasis	8.35e-05	0.000362	CcSEcCtD
Ponatinib—Malnutrition—Prednisone—psoriasis	8.29e-05	0.00036	CcSEcCtD
Ponatinib—Erythema—Prednisone—psoriasis	8.29e-05	0.00036	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	8.29e-05	0.00036	CcSEcCtD
Ponatinib—Hyperhidrosis—Triamcinolone—psoriasis	8.28e-05	0.000359	CcSEcCtD
Ponatinib—Insomnia—Hydrocortisone—psoriasis	8.23e-05	0.000357	CcSEcCtD
Ponatinib—Hypertension—Dexamethasone—psoriasis	8.22e-05	0.000357	CcSEcCtD
Ponatinib—Hypertension—Betamethasone—psoriasis	8.22e-05	0.000357	CcSEcCtD
Ponatinib—Paraesthesia—Hydrocortisone—psoriasis	8.17e-05	0.000354	CcSEcCtD
Ponatinib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	8.17e-05	0.000354	CcSEcCtD
Ponatinib—Myalgia—Dexamethasone—psoriasis	8.11e-05	0.000352	CcSEcCtD
Ponatinib—Myalgia—Betamethasone—psoriasis	8.11e-05	0.000352	CcSEcCtD
Ponatinib—Abdominal pain—Cyclosporine—psoriasis	8.09e-05	0.000351	CcSEcCtD
Ponatinib—Body temperature increased—Cyclosporine—psoriasis	8.09e-05	0.000351	CcSEcCtD
Ponatinib—Vomiting—Mycophenolic acid—psoriasis	8.05e-05	0.000349	CcSEcCtD
Ponatinib—Dyspepsia—Hydrocortisone—psoriasis	8.01e-05	0.000347	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—psoriasis	8e-05	0.000347	CcSEcCtD
Ponatinib—Rash—Mycophenolic acid—psoriasis	7.98e-05	0.000346	CcSEcCtD
Ponatinib—Dermatitis—Mycophenolic acid—psoriasis	7.97e-05	0.000346	CcSEcCtD
Ponatinib—Pain—Prednisolone—psoriasis	7.97e-05	0.000346	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—psoriasis	7.96e-05	0.000345	CcSEcCtD
Ponatinib—Headache—Mycophenolic acid—psoriasis	7.93e-05	0.000344	CcSEcCtD
Ponatinib—Decreased appetite—Hydrocortisone—psoriasis	7.91e-05	0.000343	CcSEcCtD
Ponatinib—Abdominal pain—Mycophenolate mofetil—psoriasis	7.89e-05	0.000342	CcSEcCtD
Ponatinib—Body temperature increased—Mycophenolate mofetil—psoriasis	7.89e-05	0.000342	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.85e-05	0.000341	CcSEcCtD
Ponatinib—Fatigue—Hydrocortisone—psoriasis	7.84e-05	0.00034	CcSEcCtD
Ponatinib—Vision blurred—Prednisone—psoriasis	7.82e-05	0.000339	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.81e-05	0.000339	CcSEcCtD
Ponatinib—Pain—Hydrocortisone—psoriasis	7.78e-05	0.000338	CcSEcCtD
Ponatinib—Oedema—Betamethasone—psoriasis	7.77e-05	0.000337	CcSEcCtD
Ponatinib—Oedema—Dexamethasone—psoriasis	7.77e-05	0.000337	CcSEcCtD
Ponatinib—Insomnia—Triamcinolone—psoriasis	7.75e-05	0.000336	CcSEcCtD
Ponatinib—Infection—Dexamethasone—psoriasis	7.72e-05	0.000335	CcSEcCtD
Ponatinib—Infection—Betamethasone—psoriasis	7.72e-05	0.000335	CcSEcCtD
Ponatinib—Paraesthesia—Triamcinolone—psoriasis	7.69e-05	0.000334	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—psoriasis	7.67e-05	0.000333	CcSEcCtD
Ponatinib—Anaemia—Prednisone—psoriasis	7.67e-05	0.000333	CcSEcCtD
Ponatinib—Dyspnoea—Triamcinolone—psoriasis	7.64e-05	0.000331	CcSEcCtD
Ponatinib—Nervous system disorder—Betamethasone—psoriasis	7.62e-05	0.000331	CcSEcCtD
Ponatinib—Nervous system disorder—Dexamethasone—psoriasis	7.62e-05	0.000331	CcSEcCtD
Ponatinib—Thrombocytopenia—Dexamethasone—psoriasis	7.61e-05	0.00033	CcSEcCtD
Ponatinib—Thrombocytopenia—Betamethasone—psoriasis	7.61e-05	0.00033	CcSEcCtD
Ponatinib—Dyspepsia—Triamcinolone—psoriasis	7.54e-05	0.000327	CcSEcCtD
Ponatinib—Nausea—Mycophenolic acid—psoriasis	7.52e-05	0.000326	CcSEcCtD
Ponatinib—Hyperhidrosis—Dexamethasone—psoriasis	7.51e-05	0.000326	CcSEcCtD
Ponatinib—Hyperhidrosis—Betamethasone—psoriasis	7.51e-05	0.000326	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—psoriasis	7.44e-05	0.000323	CcSEcCtD
Ponatinib—Gastrointestinal pain—Hydrocortisone—psoriasis	7.44e-05	0.000323	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—psoriasis	7.39e-05	0.000321	CcSEcCtD
Ponatinib—Fatigue—Triamcinolone—psoriasis	7.39e-05	0.00032	CcSEcCtD
Ponatinib—Asthenia—Cyclosporine—psoriasis	7.34e-05	0.000319	CcSEcCtD
Ponatinib—Pain—Triamcinolone—psoriasis	7.33e-05	0.000318	CcSEcCtD
Ponatinib—Pruritus—Cyclosporine—psoriasis	7.24e-05	0.000314	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—psoriasis	7.22e-05	0.000313	CcSEcCtD
Ponatinib—Abdominal pain—Hydrocortisone—psoriasis	7.19e-05	0.000312	CcSEcCtD
Ponatinib—Body temperature increased—Hydrocortisone—psoriasis	7.19e-05	0.000312	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—psoriasis	7.18e-05	0.000311	CcSEcCtD
Ponatinib—Asthenia—Mycophenolate mofetil—psoriasis	7.17e-05	0.000311	CcSEcCtD
Ponatinib—Hypertension—Prednisone—psoriasis	7.16e-05	0.000311	CcSEcCtD
Ponatinib—Chills—Methotrexate—psoriasis	7.14e-05	0.00031	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Dexamethasone—psoriasis	7.08e-05	0.000307	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Betamethasone—psoriasis	7.08e-05	0.000307	CcSEcCtD
Ponatinib—Pruritus—Mycophenolate mofetil—psoriasis	7.07e-05	0.000307	CcSEcCtD
Ponatinib—Arthralgia—Prednisone—psoriasis	7.06e-05	0.000306	CcSEcCtD
Ponatinib—Myalgia—Prednisone—psoriasis	7.06e-05	0.000306	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—psoriasis	7.04e-05	0.000305	CcSEcCtD
Ponatinib—Insomnia—Dexamethasone—psoriasis	7.03e-05	0.000305	CcSEcCtD
Ponatinib—Insomnia—Betamethasone—psoriasis	7.03e-05	0.000305	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	7.01e-05	0.000304	CcSEcCtD
Ponatinib—Diarrhoea—Cyclosporine—psoriasis	7e-05	0.000304	CcSEcCtD
Ponatinib—Paraesthesia—Dexamethasone—psoriasis	6.98e-05	0.000303	CcSEcCtD
Ponatinib—Paraesthesia—Betamethasone—psoriasis	6.98e-05	0.000303	CcSEcCtD
Ponatinib—Mental disorder—Methotrexate—psoriasis	6.98e-05	0.000303	CcSEcCtD
Ponatinib—Erythema—Methotrexate—psoriasis	6.93e-05	0.000301	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—psoriasis	6.93e-05	0.000301	CcSEcCtD
Ponatinib—Dyspepsia—Dexamethasone—psoriasis	6.84e-05	0.000297	CcSEcCtD
Ponatinib—Dyspepsia—Betamethasone—psoriasis	6.84e-05	0.000297	CcSEcCtD
Ponatinib—Diarrhoea—Mycophenolate mofetil—psoriasis	6.83e-05	0.000296	CcSEcCtD
Ponatinib—Body temperature increased—Triamcinolone—psoriasis	6.77e-05	0.000294	CcSEcCtD
Ponatinib—Dizziness—Cyclosporine—psoriasis	6.77e-05	0.000294	CcSEcCtD
Ponatinib—Oedema—Prednisone—psoriasis	6.77e-05	0.000294	CcSEcCtD
Ponatinib—Decreased appetite—Dexamethasone—psoriasis	6.76e-05	0.000293	CcSEcCtD
Ponatinib—Decreased appetite—Betamethasone—psoriasis	6.76e-05	0.000293	CcSEcCtD
Ponatinib—Infection—Prednisone—psoriasis	6.73e-05	0.000292	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Dexamethasone—psoriasis	6.71e-05	0.000291	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Betamethasone—psoriasis	6.71e-05	0.000291	CcSEcCtD
Ponatinib—Back pain—Methotrexate—psoriasis	6.71e-05	0.000291	CcSEcCtD
Ponatinib—Fatigue—Dexamethasone—psoriasis	6.7e-05	0.000291	CcSEcCtD
Ponatinib—Fatigue—Betamethasone—psoriasis	6.7e-05	0.000291	CcSEcCtD
Ponatinib—Pain—Dexamethasone—psoriasis	6.65e-05	0.000288	CcSEcCtD
Ponatinib—Pain—Betamethasone—psoriasis	6.65e-05	0.000288	CcSEcCtD
Ponatinib—Nervous system disorder—Prednisone—psoriasis	6.64e-05	0.000288	CcSEcCtD
Ponatinib—Dizziness—Mycophenolate mofetil—psoriasis	6.6e-05	0.000286	CcSEcCtD
Ponatinib—Skin disorder—Prednisone—psoriasis	6.58e-05	0.000285	CcSEcCtD
Ponatinib—Hyperhidrosis—Prednisone—psoriasis	6.54e-05	0.000284	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—psoriasis	6.53e-05	0.000283	CcSEcCtD
Ponatinib—Asthenia—Hydrocortisone—psoriasis	6.53e-05	0.000283	CcSEcCtD
Ponatinib—Vomiting—Cyclosporine—psoriasis	6.51e-05	0.000282	CcSEcCtD
Ponatinib—Rash—Cyclosporine—psoriasis	6.45e-05	0.00028	CcSEcCtD
Ponatinib—Dermatitis—Cyclosporine—psoriasis	6.45e-05	0.00028	CcSEcCtD
Ponatinib—Pruritus—Hydrocortisone—psoriasis	6.44e-05	0.000279	CcSEcCtD
Ponatinib—Headache—Cyclosporine—psoriasis	6.41e-05	0.000278	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—psoriasis	6.41e-05	0.000278	CcSEcCtD
Ponatinib—Gastrointestinal pain—Dexamethasone—psoriasis	6.36e-05	0.000276	CcSEcCtD
Ponatinib—Gastrointestinal pain—Betamethasone—psoriasis	6.36e-05	0.000276	CcSEcCtD
Ponatinib—Vomiting—Mycophenolate mofetil—psoriasis	6.35e-05	0.000275	CcSEcCtD
Ponatinib—Rash—Mycophenolate mofetil—psoriasis	6.3e-05	0.000273	CcSEcCtD
Ponatinib—Dermatitis—Mycophenolate mofetil—psoriasis	6.29e-05	0.000273	CcSEcCtD
Ponatinib—Headache—Mycophenolate mofetil—psoriasis	6.26e-05	0.000271	CcSEcCtD
Ponatinib—Diarrhoea—Hydrocortisone—psoriasis	6.22e-05	0.00027	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—psoriasis	6.2e-05	0.000269	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Prednisone—psoriasis	6.17e-05	0.000268	CcSEcCtD
Ponatinib—Dizziness—Prednisolone—psoriasis	6.16e-05	0.000267	CcSEcCtD
Ponatinib—Asthenia—Triamcinolone—psoriasis	6.15e-05	0.000267	CcSEcCtD
Ponatinib—Body temperature increased—Dexamethasone—psoriasis	6.14e-05	0.000267	CcSEcCtD
Ponatinib—Abdominal pain—Dexamethasone—psoriasis	6.14e-05	0.000267	CcSEcCtD
Ponatinib—Body temperature increased—Betamethasone—psoriasis	6.14e-05	0.000267	CcSEcCtD
Ponatinib—Abdominal pain—Betamethasone—psoriasis	6.14e-05	0.000267	CcSEcCtD
Ponatinib—Insomnia—Prednisone—psoriasis	6.12e-05	0.000266	CcSEcCtD
Ponatinib—Nausea—Cyclosporine—psoriasis	6.08e-05	0.000264	CcSEcCtD
Ponatinib—Paraesthesia—Prednisone—psoriasis	6.08e-05	0.000264	CcSEcCtD
Ponatinib—Pruritus—Triamcinolone—psoriasis	6.06e-05	0.000263	CcSEcCtD
Ponatinib—Cough—Methotrexate—psoriasis	6.05e-05	0.000262	CcSEcCtD
Ponatinib—Dizziness—Hydrocortisone—psoriasis	6.02e-05	0.000261	CcSEcCtD
Ponatinib—Dyspepsia—Prednisone—psoriasis	5.96e-05	0.000259	CcSEcCtD
Ponatinib—Nausea—Mycophenolate mofetil—psoriasis	5.93e-05	0.000257	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—psoriasis	5.9e-05	0.000256	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—psoriasis	5.9e-05	0.000256	CcSEcCtD
Ponatinib—Decreased appetite—Prednisone—psoriasis	5.88e-05	0.000255	CcSEcCtD
Ponatinib—Rash—Prednisolone—psoriasis	5.87e-05	0.000255	CcSEcCtD
Ponatinib—Dermatitis—Prednisolone—psoriasis	5.87e-05	0.000255	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.86e-05	0.000254	CcSEcCtD
Ponatinib—Fatigue—Prednisone—psoriasis	5.84e-05	0.000253	CcSEcCtD
Ponatinib—Headache—Prednisolone—psoriasis	5.84e-05	0.000253	CcSEcCtD
Ponatinib—Constipation—Prednisone—psoriasis	5.79e-05	0.000251	CcSEcCtD
Ponatinib—Vomiting—Hydrocortisone—psoriasis	5.78e-05	0.000251	CcSEcCtD
Ponatinib—Rash—Hydrocortisone—psoriasis	5.74e-05	0.000249	CcSEcCtD
Ponatinib—Dermatitis—Hydrocortisone—psoriasis	5.73e-05	0.000249	CcSEcCtD
Ponatinib—Headache—Hydrocortisone—psoriasis	5.7e-05	0.000247	CcSEcCtD
Ponatinib—Dizziness—Triamcinolone—psoriasis	5.67e-05	0.000246	CcSEcCtD
Ponatinib—Infection—Methotrexate—psoriasis	5.62e-05	0.000244	CcSEcCtD
Ponatinib—Asthenia—Dexamethasone—psoriasis	5.58e-05	0.000242	CcSEcCtD
Ponatinib—Asthenia—Betamethasone—psoriasis	5.58e-05	0.000242	CcSEcCtD
Ponatinib—Nervous system disorder—Methotrexate—psoriasis	5.55e-05	0.000241	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—psoriasis	5.54e-05	0.00024	CcSEcCtD
Ponatinib—Gastrointestinal pain—Prednisone—psoriasis	5.54e-05	0.00024	CcSEcCtD
Ponatinib—Nausea—Prednisolone—psoriasis	5.53e-05	0.00024	CcSEcCtD
Ponatinib—Pruritus—Betamethasone—psoriasis	5.5e-05	0.000239	CcSEcCtD
Ponatinib—Pruritus—Dexamethasone—psoriasis	5.5e-05	0.000239	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—psoriasis	5.5e-05	0.000238	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—psoriasis	5.47e-05	0.000237	CcSEcCtD
Ponatinib—Vomiting—Triamcinolone—psoriasis	5.45e-05	0.000236	CcSEcCtD
Ponatinib—Nausea—Hydrocortisone—psoriasis	5.4e-05	0.000234	CcSEcCtD
Ponatinib—Rash—Triamcinolone—psoriasis	5.4e-05	0.000234	CcSEcCtD
Ponatinib—Dermatitis—Triamcinolone—psoriasis	5.4e-05	0.000234	CcSEcCtD
Ponatinib—Headache—Triamcinolone—psoriasis	5.37e-05	0.000233	CcSEcCtD
Ponatinib—Abdominal pain—Prednisone—psoriasis	5.35e-05	0.000232	CcSEcCtD
Ponatinib—Body temperature increased—Prednisone—psoriasis	5.35e-05	0.000232	CcSEcCtD
Ponatinib—Diarrhoea—Betamethasone—psoriasis	5.32e-05	0.000231	CcSEcCtD
Ponatinib—Diarrhoea—Dexamethasone—psoriasis	5.32e-05	0.000231	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methotrexate—psoriasis	5.15e-05	0.000224	CcSEcCtD
Ponatinib—Dizziness—Dexamethasone—psoriasis	5.14e-05	0.000223	CcSEcCtD
Ponatinib—Dizziness—Betamethasone—psoriasis	5.14e-05	0.000223	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—psoriasis	5.12e-05	0.000222	CcSEcCtD
Ponatinib—Nausea—Triamcinolone—psoriasis	5.09e-05	0.000221	CcSEcCtD
Ponatinib—Paraesthesia—Methotrexate—psoriasis	5.08e-05	0.00022	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—psoriasis	5.04e-05	0.000219	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—psoriasis	4.98e-05	0.000216	CcSEcCtD
Ponatinib—Vomiting—Betamethasone—psoriasis	4.94e-05	0.000214	CcSEcCtD
Ponatinib—Vomiting—Dexamethasone—psoriasis	4.94e-05	0.000214	CcSEcCtD
Ponatinib—Decreased appetite—Methotrexate—psoriasis	4.92e-05	0.000213	CcSEcCtD
Ponatinib—Rash—Dexamethasone—psoriasis	4.9e-05	0.000213	CcSEcCtD
Ponatinib—Rash—Betamethasone—psoriasis	4.9e-05	0.000213	CcSEcCtD
Ponatinib—Dermatitis—Betamethasone—psoriasis	4.9e-05	0.000212	CcSEcCtD
Ponatinib—Dermatitis—Dexamethasone—psoriasis	4.9e-05	0.000212	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Methotrexate—psoriasis	4.88e-05	0.000212	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—psoriasis	4.88e-05	0.000212	CcSEcCtD
Ponatinib—Headache—Betamethasone—psoriasis	4.87e-05	0.000211	CcSEcCtD
Ponatinib—Headache—Dexamethasone—psoriasis	4.87e-05	0.000211	CcSEcCtD
Ponatinib—Asthenia—Prednisone—psoriasis	4.86e-05	0.000211	CcSEcCtD
Ponatinib—Pain—Methotrexate—psoriasis	4.84e-05	0.00021	CcSEcCtD
Ponatinib—Pruritus—Prednisone—psoriasis	4.79e-05	0.000208	CcSEcCtD
Ponatinib—Diarrhoea—Prednisone—psoriasis	4.63e-05	0.000201	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—psoriasis	4.63e-05	0.000201	CcSEcCtD
Ponatinib—Nausea—Dexamethasone—psoriasis	4.62e-05	0.0002	CcSEcCtD
Ponatinib—Nausea—Betamethasone—psoriasis	4.62e-05	0.0002	CcSEcCtD
Ponatinib—Dizziness—Prednisone—psoriasis	4.48e-05	0.000194	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—psoriasis	4.47e-05	0.000194	CcSEcCtD
Ponatinib—Body temperature increased—Methotrexate—psoriasis	4.47e-05	0.000194	CcSEcCtD
Ponatinib—Vomiting—Prednisone—psoriasis	4.3e-05	0.000187	CcSEcCtD
Ponatinib—Rash—Prednisone—psoriasis	4.27e-05	0.000185	CcSEcCtD
Ponatinib—Dermatitis—Prednisone—psoriasis	4.26e-05	0.000185	CcSEcCtD
Ponatinib—Headache—Prednisone—psoriasis	4.24e-05	0.000184	CcSEcCtD
Ponatinib—Asthenia—Methotrexate—psoriasis	4.06e-05	0.000176	CcSEcCtD
Ponatinib—Nausea—Prednisone—psoriasis	4.02e-05	0.000174	CcSEcCtD
Ponatinib—Pruritus—Methotrexate—psoriasis	4e-05	0.000174	CcSEcCtD
Ponatinib—Diarrhoea—Methotrexate—psoriasis	3.87e-05	0.000168	CcSEcCtD
Ponatinib—Dizziness—Methotrexate—psoriasis	3.74e-05	0.000162	CcSEcCtD
Ponatinib—Vomiting—Methotrexate—psoriasis	3.6e-05	0.000156	CcSEcCtD
Ponatinib—Rash—Methotrexate—psoriasis	3.57e-05	0.000155	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—psoriasis	3.56e-05	0.000155	CcSEcCtD
Ponatinib—Headache—Methotrexate—psoriasis	3.54e-05	0.000154	CcSEcCtD
Ponatinib—Nausea—Methotrexate—psoriasis	3.36e-05	0.000146	CcSEcCtD
Ponatinib—FGFR2—Disease—TYK2—psoriasis	1.24e-05	7.67e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IFNG—psoriasis	1.23e-05	7.64e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.23e-05	7.64e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—TYK2—psoriasis	1.22e-05	7.54e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—VEGFA—psoriasis	1.22e-05	7.53e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CD4—psoriasis	1.21e-05	7.52e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—NFKB1—psoriasis	1.21e-05	7.49e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HLA-B—psoriasis	1.21e-05	7.49e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CRP—psoriasis	1.21e-05	7.48e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—NFKB1—psoriasis	1.21e-05	7.47e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—VEGFA—psoriasis	1.21e-05	7.47e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—STAT3—psoriasis	1.19e-05	7.4e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—CD4—psoriasis	1.19e-05	7.38e-05	CbGpPWpGaD
Ponatinib—FGFR4—Disease—IL6—psoriasis	1.19e-05	7.38e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CD4—psoriasis	1.19e-05	7.37e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.19e-05	7.37e-05	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—IL6—psoriasis	1.19e-05	7.37e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—IL6—psoriasis	1.18e-05	7.33e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—IL6—psoriasis	1.18e-05	7.28e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IFNG—psoriasis	1.17e-05	7.25e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—HLA-A—psoriasis	1.17e-05	7.24e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IFNG—psoriasis	1.17e-05	7.24e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PPARG—psoriasis	1.17e-05	7.22e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—NFKB1—psoriasis	1.16e-05	7.18e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—HLA-DRB1—psoriasis	1.16e-05	7.16e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—TYK2—psoriasis	1.15e-05	7.15e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—TYK2—psoriasis	1.15e-05	7.13e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CARM1—psoriasis	1.15e-05	7.12e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CAT—psoriasis	1.14e-05	7.06e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—LEP—psoriasis	1.14e-05	7.04e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—APOE—psoriasis	1.14e-05	7.04e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD4—psoriasis	1.13e-05	7.01e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD4—psoriasis	1.13e-05	6.99e-05	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—IL6—psoriasis	1.13e-05	6.98e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TP53—psoriasis	1.12e-05	6.94e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HLA-A—psoriasis	1.12e-05	6.94e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—CD4—psoriasis	1.12e-05	6.94e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—LEP—psoriasis	1.12e-05	6.91e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—APOE—psoriasis	1.12e-05	6.91e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TP53—psoriasis	1.12e-05	6.91e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—ICAM1—psoriasis	1.11e-05	6.87e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—JUN—psoriasis	1.11e-05	6.87e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—IL6—psoriasis	1.11e-05	6.85e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—NFKBIA—psoriasis	1.1e-05	6.82e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—CD4—psoriasis	1.1e-05	6.82e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—TYK2—psoriasis	1.1e-05	6.82e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TYK2—psoriasis	1.1e-05	6.81e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CXCL8—psoriasis	1.1e-05	6.8e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—VEGFA—psoriasis	1.1e-05	6.8e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—TYK2—psoriasis	1.09e-05	6.78e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—APOE—psoriasis	1.09e-05	6.76e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—STAT3—psoriasis	1.09e-05	6.73e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—JUN—psoriasis	1.09e-05	6.73e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—VEGFA—psoriasis	1.08e-05	6.67e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.07e-05	6.65e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CRP—psoriasis	1.07e-05	6.62e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—NFKB1—psoriasis	1.07e-05	6.62e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—JUN—psoriasis	1.07e-05	6.61e-05	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—IL6—psoriasis	1.06e-05	6.59e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—APOE—psoriasis	1.06e-05	6.56e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—LEP—psoriasis	1.06e-05	6.56e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NFKBIA—psoriasis	1.06e-05	6.56e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—LEP—psoriasis	1.06e-05	6.55e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—APOE—psoriasis	1.06e-05	6.55e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—IL6—psoriasis	1.05e-05	6.51e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.05e-05	6.5e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—IL6—psoriasis	1.05e-05	6.49e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—IL6—psoriasis	1.05e-05	6.48e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—NFKB1—psoriasis	1.05e-05	6.48e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—CD4—psoriasis	1.04e-05	6.47e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—CD4—psoriasis	1.04e-05	6.45e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—IL6—psoriasis	1.04e-05	6.45e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NFKBIA—psoriasis	1.04e-05	6.44e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SOCS1—psoriasis	1.03e-05	6.41e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HLA-A—psoriasis	1.03e-05	6.41e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IFNG—psoriasis	1.03e-05	6.38e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—NFKB1—psoriasis	1.03e-05	6.36e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—NFKB1—psoriasis	1.03e-05	6.35e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IFNG—psoriasis	1.03e-05	6.35e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HLA-DRB1—psoriasis	1.02e-05	6.34e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—JUN—psoriasis	1.02e-05	6.32e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NOS2—psoriasis	1.02e-05	6.3e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—JUN—psoriasis	1.01e-05	6.27e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—JUN—psoriasis	1.01e-05	6.25e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CARM1—psoriasis	1e-05	6.2e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD4—psoriasis	9.95e-06	6.16e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD4—psoriasis	9.9e-06	6.13e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NFKBIA—psoriasis	9.87e-06	6.11e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NFKBIA—psoriasis	9.84e-06	6.1e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—NFKB1—psoriasis	9.82e-06	6.09e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—ICAM1—psoriasis	9.82e-06	6.09e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NFKBIA—psoriasis	9.74e-06	6.04e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—NFKB1—psoriasis	9.74e-06	6.04e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—NFKB1—psoriasis	9.72e-06	6.02e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—APOE—psoriasis	9.65e-06	5.98e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CXCL8—psoriasis	9.56e-06	5.93e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL6—psoriasis	9.54e-06	5.91e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CARM1—psoriasis	9.43e-06	5.84e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TNF—psoriasis	9.4e-06	5.83e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—STAT3—psoriasis	9.39e-06	5.82e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—APOE—psoriasis	9.32e-06	5.77e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—LEP—psoriasis	9.32e-06	5.77e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—IL6—psoriasis	9.24e-06	5.72e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—STAT3—psoriasis	9.22e-06	5.72e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—IL6—psoriasis	9.19e-06	5.7e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—psoriasis	9.19e-06	5.69e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SOCS1—psoriasis	9.16e-06	5.68e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—psoriasis	9.11e-06	5.64e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—TYK2—psoriasis	9.02e-06	5.59e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NOS2—psoriasis	9e-06	5.57e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—VEGFA—psoriasis	8.92e-06	5.52e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—JUN—psoriasis	8.9e-06	5.52e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—JUN—psoriasis	8.89e-06	5.51e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—JUN—psoriasis	8.86e-06	5.49e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—APOE—psoriasis	8.85e-06	5.48e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—STAT3—psoriasis	8.83e-06	5.47e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—IL6—psoriasis	8.81e-06	5.46e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—STAT3—psoriasis	8.75e-06	5.42e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—STAT3—psoriasis	8.73e-06	5.41e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NFKBIA—psoriasis	8.68e-06	5.38e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TYK2—psoriasis	8.67e-06	5.37e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—STAT3—psoriasis	8.67e-06	5.37e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—NFKB1—psoriasis	8.57e-06	5.31e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—NFKB1—psoriasis	8.56e-06	5.3e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—NFKB1—psoriasis	8.53e-06	5.29e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TYK2—psoriasis	8.52e-06	5.28e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—STAT3—psoriasis	8.52e-06	5.28e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IFNG—psoriasis	8.44e-06	5.23e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IL6—psoriasis	8.34e-06	5.17e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—TYK2—psoriasis	8.32e-06	5.16e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CAT—psoriasis	8.16e-06	5.06e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD4—psoriasis	8.15e-06	5.05e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—psoriasis	8.13e-06	5.04e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TYK2—psoriasis	8.08e-06	5.01e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—STAT3—psoriasis	8.08e-06	5.01e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TYK2—psoriasis	8.06e-06	5e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—STAT3—psoriasis	8.06e-06	5e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—TYK2—psoriasis	7.98e-06	4.95e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—VEGFA—psoriasis	7.77e-06	4.81e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PPARG—psoriasis	7.71e-06	4.78e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—STAT3—psoriasis	7.7e-06	4.77e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—STAT3—psoriasis	7.69e-06	4.77e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—STAT3—psoriasis	7.67e-06	4.75e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—LEP—psoriasis	7.64e-06	4.73e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—APOE—psoriasis	7.64e-06	4.73e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—IL6—psoriasis	7.59e-06	4.7e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—IL6—psoriasis	7.57e-06	4.69e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CXCL8—psoriasis	7.55e-06	4.68e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CD4—psoriasis	7.53e-06	4.66e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IFNG—psoriasis	7.47e-06	4.63e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CXCL8—psoriasis	7.42e-06	4.59e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—TYK2—psoriasis	7.37e-06	4.57e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—JUN—psoriasis	7.3e-06	4.52e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD4—psoriasis	7.22e-06	4.47e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NFKBIA—psoriasis	7.12e-06	4.41e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TYK2—psoriasis	7.11e-06	4.41e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CAT—psoriasis	7.07e-06	4.38e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CXCL8—psoriasis	7.04e-06	4.36e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—NFKB1—psoriasis	7.02e-06	4.35e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CXCL8—psoriasis	7.02e-06	4.35e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—JUN—psoriasis	7.02e-06	4.35e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—JUN—psoriasis	6.89e-06	4.27e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APOE—psoriasis	6.76e-06	4.19e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—LEP—psoriasis	6.76e-06	4.19e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NFKB1—psoriasis	6.76e-06	4.19e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—psoriasis	6.74e-06	4.17e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—IL6—psoriasis	6.7e-06	4.15e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CD4—psoriasis	6.66e-06	4.13e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NFKB1—psoriasis	6.64e-06	4.11e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL6—psoriasis	6.56e-06	4.06e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—JUN—psoriasis	6.54e-06	4.05e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—JUN—psoriasis	6.53e-06	4.04e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—JUN—psoriasis	6.46e-06	4e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL6—psoriasis	6.44e-06	3.99e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOE—psoriasis	6.34e-06	3.93e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—STAT3—psoriasis	6.31e-06	3.91e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NFKBIA—psoriasis	6.3e-06	3.9e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NFKB1—psoriasis	6.3e-06	3.9e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NFKB1—psoriasis	6.28e-06	3.89e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NFKB1—psoriasis	6.22e-06	3.85e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL8—psoriasis	6.19e-06	3.84e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—psoriasis	6.17e-06	3.82e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CARM1—psoriasis	6.17e-06	3.82e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CAT—psoriasis	6.16e-06	3.81e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—psoriasis	6.13e-06	3.8e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—psoriasis	6.11e-06	3.79e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—psoriasis	6.1e-06	3.78e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—STAT3—psoriasis	6.07e-06	3.76e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—psoriasis	6.06e-06	3.75e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—psoriasis	6.02e-06	3.73e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—STAT3—psoriasis	5.96e-06	3.7e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—psoriasis	5.95e-06	3.69e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—psoriasis	5.87e-06	3.64e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TYK2—psoriasis	5.83e-06	3.61e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—STAT3—psoriasis	5.83e-06	3.61e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CAT—psoriasis	5.8e-06	3.59e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—JUN—psoriasis	5.76e-06	3.57e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—psoriasis	5.72e-06	3.54e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—psoriasis	5.7e-06	3.53e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STAT3—psoriasis	5.66e-06	3.51e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—psoriasis	5.65e-06	3.5e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STAT3—psoriasis	5.65e-06	3.5e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—psoriasis	5.63e-06	3.49e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—STAT3—psoriasis	5.59e-06	3.46e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NFKB1—psoriasis	5.54e-06	3.43e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARG—psoriasis	5.52e-06	3.42e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOE—psoriasis	5.49e-06	3.4e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—psoriasis	5.38e-06	3.33e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—psoriasis	5.37e-06	3.33e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—psoriasis	5.35e-06	3.32e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TYK2—psoriasis	5.16e-06	3.2e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—psoriasis	5.16e-06	3.2e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—psoriasis	5.07e-06	3.14e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—psoriasis	5.03e-06	3.12e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—psoriasis	4.98e-06	3.09e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOE—psoriasis	4.78e-06	2.96e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARG—psoriasis	4.78e-06	2.96e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—JUN—psoriasis	4.72e-06	2.92e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—psoriasis	4.63e-06	2.87e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—psoriasis	4.55e-06	2.82e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NFKB1—psoriasis	4.54e-06	2.81e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOE—psoriasis	4.51e-06	2.79e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—psoriasis	4.49e-06	2.78e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—psoriasis	4.41e-06	2.73e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—psoriasis	4.32e-06	2.68e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—psoriasis	4.31e-06	2.67e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—psoriasis	4.24e-06	2.63e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—JUN—psoriasis	4.18e-06	2.59e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARG—psoriasis	4.17e-06	2.58e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—psoriasis	4.17e-06	2.58e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—psoriasis	4.12e-06	2.55e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—psoriasis	4.08e-06	2.53e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—psoriasis	4.07e-06	2.52e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NFKB1—psoriasis	4.02e-06	2.49e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—psoriasis	3.95e-06	2.45e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—psoriasis	3.94e-06	2.44e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARG—psoriasis	3.93e-06	2.43e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—psoriasis	3.9e-06	2.42e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—psoriasis	3.8e-06	2.35e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAT—psoriasis	3.79e-06	2.35e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—psoriasis	3.65e-06	2.26e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—psoriasis	3.61e-06	2.24e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—psoriasis	3.6e-06	2.23e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—psoriasis	3.48e-06	2.16e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—psoriasis	3.11e-06	1.93e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOE—psoriasis	2.95e-06	1.83e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—psoriasis	2.85e-06	1.77e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—psoriasis	2.76e-06	1.71e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARG—psoriasis	2.57e-06	1.59e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—psoriasis	2.52e-06	1.56e-05	CbGpPWpGaD
